# EDGAR Filing Document

**Accession Number:** 0001872789
**File Stem:** 0000947871-26-000064
**Filing Date:** 2026-1
**Character Count:** 6782
**Document Hash:** f278455fe98c10cacef4a513bd8d1669
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000947871-26-000064.hdr.sgml**: 20260123

**ACCESSION NUMBER**: 0000947871-26-000064

**CONFORMED SUBMISSION TYPE**: DEFA14A

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20260123

**DATE AS OF CHANGE**: 20260122

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Embecta Corp.
- **CENTRAL INDEX KEY:** 0001872789
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 871583942
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 0930

**FILING VALUES:**
- **FORM TYPE:** DEFA14A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41186
- **FILM NUMBER:** 26552915

**BUSINESS ADDRESS:**
- **STREET 1:** 1209 ORANGE STREET
- **CITY:** WILMINGTON
- **STATE:** DE
- **ZIP:** 19801
- **BUSINESS PHONE:** 8624010000

**MAIL ADDRESS:**
- **STREET 1:** 1209 ORANGE STREET
- **CITY:** WILMINGTON
- **STATE:** DE
- **ZIP:** 19801

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Berra Newco, Inc.
- **DATE OF NAME CHANGE:** 20210714

**UNITED STATES<br> SECURITIES AND EXCHANGE COMMISSION<br> Washington, D.C. 20549**

**SCHEDULE 14A**

Proxy Statement Pursuant to Section 14(a) of the Securities<br> Exchange Act of 1934 (Amendment No.)

Filed by the Registrant ☑

Filed by a Party other than the Registrant ☐

Check the appropriate box:

---

| | |
|:---|:---|
| &nbsp;&nbsp;☐ | &nbsp;&nbsp;Preliminary Proxy Statement |
| &nbsp;&nbsp;☐ | &nbsp;&nbsp;**Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))** |
| &nbsp;&nbsp;☐ | &nbsp;&nbsp;Definitive Proxy Statement |
| &nbsp;&nbsp;🗹 | &nbsp;&nbsp;Definitive Additional Materials |
| &nbsp;&nbsp;☐ | &nbsp;&nbsp;Soliciting Material Pursuant to §240.14a-12 |

---

**Embecta Corp.**

(Name of Registrant as Specified In Its Charter)<br> (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check all boxes that apply):

🗹 No fee required <br> ☐ Fee paid previously with preliminary materials <br> ☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

**SUPPLEMENT TO PROXY STATEMENT DATED DECEMBER 18, 2025**

**FOR THE ANNUAL MEETING OF STOCKHOLDERS**

**TO BE HELD ON FEBRUARY 11, 2026** 

**Embecta Corp.**<br> 300 Kimball Drive, Ste 300<br> Parsippany, New Jersey 07054<br> www.embecta.com

**Dear fellow stockholders**,

The additional materials provided herein supplement, and should be read in conjunction with, the information regarding *Proposal 4 - Approval of an Amendment to the Embecta 2022 Employee and Director Equity-Based Compensation Plan* contained in the definitive proxy statement (the "Proxy Statement") of Embecta Corp. ("we," "us," "our" or the "Company") filed with the Securities and Exchange Commission on December 18, 2025, regarding the annual meeting of stockholders to be held on February 11, 2026, at 8:00 a.m. EST (the "2026 Annual Meeting"). From and after the date of this supplement, any references to the Proxy Statement will be deemed to include the Proxy Statement as supplemented hereby. Capitalized terms used herein, unless otherwise defined, have the meanings set forth in the Proxy Statement.

As more specifically described in the Proxy Statement, we are seeking stockholder approval to amend the Embecta 2022 Employee and Director Equity-Based Compensation Plan (as amended from time-to-time, the "2022 Plan"), in order to increase the number of shares available for issuance under the 2022 Plan by 2,430,000 shares (the "2022 Plan Amendment"). The 2022 Plan Amendment was approved by the Board on December 2, 2025.

On January 19, 2026, Institutional Shareholder Services ("ISS") issued its Proxy Analysis & Benchmark Policy Voting Recommendations (the "ISS Report") related to the 2026 Annual Meeting. In the ISS Report, ISS recommended that stockholders vote against the proposal to approve the 2022 Plan Amendment. The commentary below addresses certain key concerns outlined in the ISS Report and provides supplemental data to ensure our stockholders have an opportunity to vote their shares on the basis of accurate, up-to-date information.

**The 2022 Plan cost is reasonable.**

Among the reasons provided by ISS for its negative voting recommendation was the determination by ISS that the stockholder value transfer, or SVT, exceeded applicable ISS SVT benchmarks. ISS had assumed a calculation date for purposes of analyzing SVT as of September 30, 2025. We had specifically calculated our share request as of November 30, 2025. Correcting these assumptions, we believe, will bring our plan within the parameters of ISS guidelines.

Share Activity as of November 30, 2025<sup>(1)</sup>

---

| | |
|:---|:---|
| &nbsp;&nbsp;Number of Common Shares Outstanding | &nbsp;&nbsp;59211232 |
| &nbsp;&nbsp;Number of Shares Attributable to the GSIP | &nbsp;&nbsp;642942 |
| &nbsp;&nbsp;Number of Outstanding SARs | &nbsp;&nbsp;1427452 |
| &nbsp;&nbsp;Weighted Average Exercise Price | &nbsp;&nbsp;29.37 |
| &nbsp;&nbsp;Weighted Average Remaining Contractual Term (Years) | &nbsp;&nbsp;5.69 |
| &nbsp;&nbsp;Number of Outstanding TVUs | &nbsp;&nbsp;2972427 |
| &nbsp;&nbsp;Number of Outstanding PSUs<sup>(2)</sup> | &nbsp;&nbsp;1722979 |
| &nbsp;&nbsp;Share Reserve under 2022 Plan | &nbsp;&nbsp;791505 |

---

<sup>(1)</sup> All data in the table, with the exception of the Number of Shares Attributable to the GSIP, is based upon awards issued under the 2022 Plan and does not otherwise include awards issued under any other plan. No other plans have awards outstanding or shares available for future awards.

 

 

 

<sup>(2)</sup> The Company has determined that the service inception date precedes the grant date for certain PSU awards as (a) the awards were authorized prior to establishing an accounting grant date, (b) the recipients began providing services prior to the grant date, and (c) there are performance conditions that, if not met by the accounting grant date, will result in the forfeiture of the awards. The number shown here represents the full number of outstanding PSUs as of November 30, 2025, inclusive of 952,203 awards which contain targets that will be fully established at a future date.

**The Board reiterates its recommendation that you vote "FOR" the approval of Proposal 4.**

If you have already voted, you do not need to vote again unless you would like to change or revoke your prior vote on any proposal. If you would like to change or revoke your prior vote on any proposal, please refer to page 80 of the Proxy Statement for instructions on how to do so.

Sincerely,

![](image_001.jpg)

Jeff Mann

*Senior Vice President, General Counsel and Product Development*